Our innovative technology becomes available for patients
Following a successful fundraising in Q4 2016, METAFORA achieves an important milestone by announcing, in partnership with CERBA Healthcare, the availability of the METAglut1 blood test to diagnose the GLUT1 deficiency syndrome (GLUT1 DS). Through METAglut1, our disruptive technology becomes available, for the first time, to patients.
De Vivo’s disease (the other name of GLUT1 DS) is affecting mainly children and is very debilitating. This is due to a defect in the expression of GLUT1, the major glucose transporter, at the surface of cells. This is mostly dramatic at the brain level.
METAFORA has developed a blood based test that will allow the early detection of the disease and that will be performed by CERBA Healthcare. Because the disease is curable it is very important to be able to detect it early as to avoid irreversible brain damage. Today this can be achieved through our METAglut1 test.
This partnership represents a major achievement in the fight against this disease and will bring relief to numerous patients and families.
Most popular related searches
No comments were found for Our innovative technology becomes available for patients. Be the first to comment!